Company Information
Industry 制造业
Company Introduction 西藏奇正藏药股份有限公司(简称奇正藏药)是国内藏药龙头企业,主要从事新型藏药的研发、生产和销售,现拥有GMP药厂、GSP营销公司等全资及控股子公司21家,员工2974人,25个独家品种和141个药品批准文号,产品涵盖骨骼肌肉系统、神经系统、消化系统、心脑血管、呼吸系统、泌尿系统、妇科、皮肤科、儿科等领域。其中以奇正消痛贴膏为代表的外用止痛药物系列已在国内畅销多年并行销海外,临床有效率高,销售额在中国外用止痛药物市场连续多年名列前茅。 奇正藏药1995年落户西藏林芝,以千年藏药现代传承为己任,通过文化传承和科技创新带动传统藏药产业创新升级。公司被认定为首批国家创新型企业、国家级高新技术企业、国家技术创新示范企业、国家火炬计划重点高新技术企业、国家级企业技术中心,拥有两个国家地方联合实验室,先后实施国家“十一五”科技支撑计划重点项目、承担国家“十二五”、“十三五”科技重大专项。 公司在二十多年的经营实践中,秉持“向善利他正道正业”的核心价值观,自发、自觉地践行企业社会责任,始终保持动机与发心的善念,志愿维护自然和社会生态的共生共荣,形成了独具特色的可持续发展体系。截至2022年底,公司累计投入1.501亿元用于藏区和西部的医疗、教育、乡村振兴,及“新冠”疫情防控捐赠等社会公益事业。 公司自上市以来,始终专注主业,保持业绩的稳步持续增长。2022年,公司全年实现营业收入20.45亿,同比增长15.49%;归属于上市公司股东的扣除非经常性损益的净利润4.4亿元,同比增长27.57%。
Main Business 藏药的研发、生产和销售,包括外用止痛药物、口服药等
Legal Representative 刘凯列
Top Executives
董事长:刘凯列
名誉董事长:雷菊芳
董事:刘凯列,索朗欧珠,夏海建
独立董事:果德安,李春瑜,王玉荣
Top 5 Shareholder
Shareholder name Nature Holding Date
甘肃奇正实业集团有限公司流通A股68.76%30/09/2024
西藏宇妥文化发展有限公司流通A股18.56%30/09/2024
黄云流通A股0.93%30/09/2024
香港中央结算有限公司流通A股0.32%30/09/2024
叶伟流通A股0.19%30/09/2024
Company Secretary 冯平
Solicitors 北京市天银律师事务所
Auditors 利安达会计师事务所有限责任公司
Tel No 010-84766012
Fax No 010-84766081
Website www.cheezheng.com.cn
Email qzzy@qzh.cn
Company Address
Register: 西藏自治区林芝市巴宜区德吉路2号
Office: 北京市朝阳区望京北路9号叶青大厦D座七层
Listing Date 28/08/2009
Shares Capital
Shares Capital: 530,173,477
Total A Share: 530,173,477
Listed A Share: 528,971,263
Non-tradable A Share: 1,202,214
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.097
DPS(RMB)* ¥ 0.480
NBV Per Share(RMB)* ¥ 6.764
Market Capitalization(RMB) 11.934B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.